NHS England’s chief executive, Simon Stevens, recently stated that focus must be put on care in the community and in the home to tackle the huge deficits facing NHS trusts.
Novo Nordisk has partnered with Ascendis Pharma on less frequently dosed drugs for obesity and other metabolic diseases, starting with a once-monthly GLP-1 receptor agonist.